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ABSTRACT
B lymphoblastic leukemia (B-ALL) may be associated with recurrent cytogenetic and molecular abnormalities.
We describe the fourth-known case of B-ALL associated with the t(8;22)(p11.2q11.2) – a translocation seen
more frequently in T lymphoblastic leukemia and acute myelogenous leukemia. This patient’s leukemia involves
a combination of additional cytogenetic anomalies not yet described in the literature, including del(11)(q13q23),
add(9)(p22), and monosomy 7. Given the role in B cell differentiation of genes in the affected regions, including
MEN1 (11q13), ATM (11q22), ETS1(11q23), MLL (11q23), AF9 (9p22), and IKZ-F1 (7p12), this case may provide
further insight into B cell leukemogenesis associated with the t(8;22). Deletion or mutation of these genes may
be critical in targeting the B cell population, and this cytogenetic profile of a B-ALL suggests additional gene
targets for diagnostic and therapeutic consideration.

INTRODUCTION
B cell acute lymphoblastic leukemia (B-ALL)
may be associated with recurrent cytogenetic and
molecular abnormalities. We describe the fourthknown case of B-ALL associated with the
t(8;22)(p11.2q11.2) [1-3]. In addition, this B-ALL
has associated cytogenetic anomalies not yet
described in the literature; a del(11)(q13q23), an
add(9)(p22), and a monosomy 7 were also
present. Important gene groups for B cell
differentiation were identified on these
chromosomes, which may provide further insight
into B cell leukemogenesis associated with the
t(8;22).

CASE REPORT
The patient, a 78-year-old woman,
presented with a two-week history of chest pain,
shortness of breath, and severe abdominal pain
with accompanying nausea and night sweats. The
complete blood count (CBC) revealed a
leukocytosis and thrombocytopenia [white blood
cell count (WBC) 70.93x10^3/ul and platelets
13x10^3/uL] as well as anemia (hemoglobin
9.7g/dL and hematocrit 29.5%). Evaluation of the
peripheral blood smear revealed 60% blasts. The
blasts on the peripheral smear were intermediate
in size with a high nuclear/cytoplasmic ratio, ovoid
to irregular nuclei with fine chromatin, and with
inconspicuous nucleoli and scant blue cytoplasm
(Fig 1A).
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fusion of ETV6 (TEL; 12p13) and RUNX1 AML1;
21q22) regions. The patient received Rituximab, to
which she had an anaphylactic reaction. She
refused further chemotherapy and was lost to
follow-up.

DISCUSSION

Figure 1: Blast cells in peripheral blood: Wright-Giemsa stain,
50x (A). Bone marrow aspirate: Wright-Giemsa stain, 50x
(B,C). Bone marrow: hematoxylin and eosin stain, 40x (D),
mitotic figure of leukemic blast, hematoxylin and eosin
stain,100x (D inset).

Approximately 90-100% of the cells in the
bone marrow aspirate were blasts similar to those
observed in the peripheral blood (Fig 1B,C). The
bone marrow biopsy was hypercellular (90-100%)
with a monotonous infiltrate of blasts with
frequent mitotic figures (Fig 1D). Flow cytometric
analysis of the peripheral blood revealed a blast
population that was CD 10, 19, 20, 33, 34 and
HLA-DR positive, consistent with B-ALL.
Immunohistochemical staining of the bone
marrow core biopsy confirmed a population of
CD34, CD10, CD79a and CD20 positive cells (Fig 2).

Figure 2: Immunohistochemical staining of the bone marrow
core biopsy: CD10 (A), CD20 (B), CD34 (C), CD79a (D). (All at
20x.)

Cytogenetic
analysis
revealed
a
t(8;22)(p11.2;q11.2) in all metaphases analyzed.
In addition to the translocation, 30% of this cell
population
had
additional
chromosomal
abnormalities,
including
del(11)(q13q23),
add(9)(p22) and monosomy 7. FISH showed no

B-ALL is a neoplasm of lymphoblasts
committed to the B-cell lineage. The genetic
profile of the blasts is of critical importance
regarding prognosis and therapeutic management
of the leukemic process. Considering this, the
World Health Organization has classified certain
subgroups of B-ALL according to the chromosomal
translocation expressed by the malignant
population of cells. There are several such
translocations commonly associated with B-ALL,
such as such as t(9;22) and t(12;21). These
translocations produce identifiable fusion
proteins, the downstream affects of which are
thought to influence features of this leukemia.
Whereas this has been helpful for estimating
patient outcome and determining treatment
regimen, it does not necessarily provide reliable
insight into the initial steps of leukemogenesis.
The translocation associated with a lesion may be
sufficient to drive cancer pathogenesis, but a
direct
correlation
between
translocation
expressed and the leukemia it produces is
inconsistent [4]. This suggests that along with the
chromosomal translocation, additional genetic
mechanisms are involved in determining which
blast population is affected and at which stage the
cells are arrested.
The translocation t(8;22)(p11.2q11.2) has
been shown to produce a fusion protein,
combining regions of the gene coding for
fibroblast growth factor receptor 1 (FGFR1) with
regions of the gene coding for breakpoint cluster
region (BCR). Constitutive activation of the FGFR1
kinase region is generated by the relocation of this
region to a location downstream of the BCR region
in t(8;22)(p11.2q11.2). The activity of this fusion
protein has been previously shown to arrest the
neoplastic population at an early B-cell stage [5].
In addition, it allows this population to proliferate
in a cytokine independent manner [6] conferring
oncogenic potential. The mechanisms underlying
these capabilities have yet to be fully elucidated,
but studies have identified some aspects of the
molecular activity. For example, the BCR-FGFR1
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protein has been shown to constitutively activate
STAT5, which may underlie the cytokine
independence of the cells and the subsequent
ability of this population to survive and expand
[7].
Despite this evidence that BCR-FGFR1 has
the ability to manifest in a B-cell population, the
diagnosis in the majority of reported cases with
the translocation producing this fusion protein has
clinical features
that resemble chronic
myelogenous leukemia (CML). This disease is
aggressive and rapidly evolves to acute
myelogenous leukemia (AML) or less commonly to
T lymphoblastic leukemia (T-ALL). Understanding
the leukemogenesis in this case of B-ALL, then,
necessitates a closer look at the other cytogenetic
anomalies identified in the blast population and
their potential contribution to the actions of the
BCR-FGFR1 fusion protein.
Here, we consider the cytogenetic profile of
the presented case.
In addition to the
t(8;22)(p11.2;q11.2) karyotype, 30% of the cells
revealed
three
additional
chromosomal
abnormalities, del(11)(q13q23), add(9)(p22) and
monosomy 7. Each of these affected regions
harbors genes that participate in normal B cell
development, and deletion or mutation within
these gene regions may therefore have
implications in the pathogenesis or progression of
this B cell leukemic process. Within the region of
the 11q deletion, there are several candidate
genes including MEN1 (11q13), ATM (11q22),
ETS1(11q23), and MLL (11q23) that have been
shown to play critical roles in B cell differentiation.
The MEN1 gene codes for menin, a protein
involved in regulation of B lymphoid progenitor
differentiation by regulating Hoxa9 expression.
Loss of menin function has been associated with
impaired B lymphoid progenitor development. In
addition, the interaction of menin with MLL fusion
proteins is well-documented and may be of
interest in our case, as MLL is also within the
region of the 11q deletion. The MLL protein is an
important component of hematopoiesis -- it acts
as part of a complex of proteins that also includes
menin to dictate cell fate of progenitor cells
through Hox gene expression regulation [8].
Disruption of the MLL gene at 11q23 is
characteristic of well-recognized subsets of acute
leukemia, often associated with blast cells that
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generate MLL fusion proteins.
The blast
populations produced are arrested at an early
progenitor stage and proliferate in response to
increased levels of Hox9, itself driven by MLL
fusion proteins. MLL translocation can be cryptic,
often presenting as an 11q23 deletion, detectable
only if further studies are performed, such as
multiplex FISH analysis [9]. Additional analysis
was not performed in this case; however,
especially with the finding of addition at 9p22
harboring AF9, a frequent MLL fusion partner,
identification of MLL translocation in this cell
population may have had implications for
diagnosis and treatment.
ATM, ETS1 and IKZ-F1 gene deletions have
also
been
linked
to
leukemic
B-cell
transformation. Deletion of these genes interfere
with pre-B cell receptor function, inhibiting
signaling that is critical to induce the switch from
early B cell proliferation to differentiation [10-12].
Of note and relevant to the monosomy 7 present
in the current report, IKZ-F1(7p12.2) may be
particularly important in targeting B-cells for
transformation to leukemia. IKZ-F1 codes for
Ikaros, a protein that is required for the ability of
the pre-B cell receptor to induce B-cell
differentiation, possibly through activation of SLP65. Deficiency of SLP-65 has been linked to pre-B
cell proliferation and pre-B-cell leukemogenesis.
The applicability of this information may be
further clarified through consideration of recent
data examining mechanisms underlying BCR-ABL
positive B-ALL. BCR-ABL+ leukemia most often
manifests as a chronic myelogenous leukemia.
However, recent data comparing the complete
cytogenetic profiles of BCR-ABL B-ALL and BCRABL CML has revealed the presence of an IKZ-F1
mutation in 84% of BCR-ABL- induced B-ALL, a
mutation not seen in the myelogenous leukemia
type with this fusion protein. The literature on
BCR-FGFR1-induced B-ALL is comparatively sparse.
However, Baldazzi et al also described monosomy
7 as part of the cytogenetic profile in their case
report of B-ALL with a t(8;22)(p11.2q11.2) [1].

CONCLUSION
Our case suggests that the mechanism of BALL with t(8;22)(p11.2q11.2) is multifactorial. This
particular cytogenetic profile of B-ALL suggests
additional gene targets for diagnostic and
therapeutic consideration. In addition, alteration
Page 3 of 4
(Page number not for citation purposes)

Open Journal of Hematology, 2013, 4-2

of genes critical for B cell differentiation provides
insight into how the 8;22 translocation, more
commonly seen in myelogenous as well as T cell
leukemia, may also be associated with disruptions
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in B cell leukemogenesis.
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